GSK2606414

CAS No. 1337531-36-8

GSK2606414( GSK2606414 | GSK-2606414 | GSK PERK Inhibitor )

Catalog No. M11350 CAS No. 1337531-36-8

GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 55 In Stock
5MG 86 In Stock
10MG 116 In Stock
50MG 314 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK2606414
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM.
  • Description
    GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM, displaying at least 100-fold selectivity over the other EIF2AKs assayed.(In Vitro):GSK2606414 inhibits PERK activation in cells.(In Vivo):GSK2606414 (50 and 150 mg/kg, p.o.) inhibits the growth of a human tumor xenograft in mice.
  • In Vitro
    GSK2606414 inhibits PERK activation in cells.
  • In Vivo
    GSK2606414 (50 and 150 mg/kg, p.o.) inhibits the growth of a human tumor xenograft in mice.
  • Synonyms
    GSK2606414 | GSK-2606414 | GSK PERK Inhibitor
  • Pathway
    Apoptosis
  • Target
    PERK
  • Recptor
    eIF-2AK1 (HRI)| eIF-2AK2 (PKR)| eIF-2AK3 (PERK)
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1337531-36-8
  • Formula Weight
    451.44
  • Molecular Formula
    C24H20F3N5O
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 19 mg/mL (42.08 mM); DMSO: 90 mg/mL (199.36 mM)
  • SMILES
    FC(C1=CC(CC(N2CCC3=C2C=CC(C4=CN(C)C5=NC=NC(N)=C54)=C3)=O)=CC=C1)(F)F
  • Chemical Name
    1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Axten JM, et al. J Med Chem. 2012, 55(16), 7193-7207.
molnova catalog
related products
  • Epieriocalyxin A

    Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.

  • 4E1rcat

    4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.

  • BTdCPU

    BTdCPU is a potent heme-regulated eIF2α kinase (HRI) activator.?BTdCPU promotes eIF2α phosphorylation and induced apoptosis in resistant cell.